Cuzzone Daniel A, Albano Nicholas J, Aschen Seth Z, Ghanta Swapna, Mehrara Babak J
The Division of Plastic and Reconstructive Surgery, Memorial Sloan-Kettering Cancer Center , New York, New York.
Lymphat Res Biol. 2015 Sep;13(3):186-94. doi: 10.1089/lrb.2013.0054. Epub 2014 Aug 21.
The lymphatic system is commonly injured during cancer treatment. However, despite the morbidity of these injuries, there are currently no options for replacing damaged lymphatics. The purpose of this study was to optimize methods for decellularization of murine lymph nodes (LN) and to determine if these scaffolds can be used to tissue engineer lymph node-like structures.
LNs were harvested from adult mice and subjected to various decellularization protocols. The degree of decellularization and removal of nuclear material was analyzed histologically and quantitatively using DNA isolation. In addition, we analyzed histological architecture by staining for matrix proteins. After the optimal method of decellularization was identified, decellularized constructs were implanted in the renal capsule of syngeneic or allogeneic recipient mice and analyzed for antigenicity. Finally, to determine if decellularized constructs could deliver lymphocytes to recipient animals, the matrices were repopulated with splenocytes, implanted in submuscular pockets, and harvested 14 days later. Decellularization was best accomplished with the detergent sodium dodecyl sulfate (SDS), resulting in negligible residual cellular material but maintenance of LN architecture. Implantation of decellularized LNs into syngeneic or allogeneic mice did not elicit a significant antigenic response. In addition, repopulation of decellularized LNs with splenocytes resulted in successful in vivo cellular delivery.
We show, for the first time, that LNs can be successfully decellularized and that these matrices have preserved extracellular matrix architecture and the potential to deliver leukocytes in vivo. Future studies are needed to determine if tissue engineered lymph nodes maintain immunologic function.
在癌症治疗过程中,淋巴系统常受到损伤。然而,尽管这些损伤会引发疾病,但目前尚无替代受损淋巴管的方法。本研究的目的是优化小鼠淋巴结(LN)去细胞化的方法,并确定这些支架是否可用于组织工程化淋巴结样结构。
从成年小鼠获取淋巴结,并对其进行各种去细胞化方案处理。通过DNA分离技术,从组织学和定量角度分析去细胞化程度及核物质的去除情况。此外,我们通过对基质蛋白进行染色来分析组织结构。确定最佳去细胞化方法后,将去细胞化构建体植入同基因或异基因受体小鼠的肾被膜中,并分析其抗原性。最后,为了确定去细胞化构建体是否能将淋巴细胞递送至受体动物体内,将这些基质重新填充脾细胞,植入肌下袋中,并在14天后收获。用十二烷基硫酸钠(SDS)去污剂能最好地实现去细胞化,残留细胞物质可忽略不计,但能维持淋巴结结构。将去细胞化的淋巴结植入同基因或异基因小鼠体内未引发显著的抗原反应。此外,用脾细胞重新填充去细胞化的淋巴结可成功实现体内细胞递送。
我们首次表明,淋巴结可成功去细胞化,且这些基质保留了细胞外基质结构,并具有在体内递送白细胞的潜力。未来需要开展研究以确定组织工程化淋巴结是否能维持免疫功能。